Therefore, the direct targeting of the NLRP3 inflammasome may prove more effective in RA treatment than blocking IL-1 activity alone, due to inhibition of both IL-1β and IL-18 signalling, as well as preventing the release of alarmins via pyroptosis (166). The gene discussed is IL1B; the disease is rheumatoid arthritis.